- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BiomX Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Do | BiomX GAAP EPS of -$0.31 beats by $0.19 | 1 | Seeking Alpha | ||
| Do | BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates | 41 | GlobeNewswire (Europe) | BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is... ► Artikel lesen | |
| BIOMX Aktie jetzt für 0€ handeln | |||||
| Do | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.11. | Biomx-Aktie stürzt auf 52-Wochen-Tief von 0,72 US-Dollar | 2 | Investing.com Deutsch | ||
| 01.11. | Biomx stock plunges to 52-week low of $0.72 amid market challenges | 3 | Investing.com | ||
| 31.10. | BiomX Inc. - 15-12G, Securities registration termination | 3 | SEC Filings | ||
| 25.10. | NSE - BiomX Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 24.10. | Biomx-Aktie stürzt auf 52-Wochen-Tief und erreicht 0,87 US-Dollar | 3 | Investing.com Deutsch | ||
| 24.10. | Biomx stock plunges to 52-week low, hits $0.87 | 1 | Investing.com | ||
| 15.10. | BiomX Announces a Mandatory Unit Separation | 53 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that... ► Artikel lesen | |
| 15.10. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.10. | Biomx stock plunges to 52-week low, hitting $0.92 | 1 | Investing.com | ||
| 26.09. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | BiomX Stock Gains From Favorable Study Data Presentation on BX004 | 1 | Zacks | ||
| 18.09. | BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference | 1 | GlobeNewswire (USA) | ||
| 12.09. | BiomX Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.09. | Biomx-Aktie stürzt auf 52-Wochen-Tief und notiert bei 1,05 US-Dollar | 1 | Investing.com Deutsch | ||
| 04.09. | BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 2 | GlobeNewswire (USA) | ||
| 16.08. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 98,50 | +0,15 % | GOLDMAN SACHS stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat Biontech von "Neutral" auf "Buy" hochgestuft und das Kursziel von 90 auf 137 US-Dollar angehoben. Analyst Chris Shibutani bezieht... ► Artikel lesen | |
| AMGEN | 281,60 | +0,12 % | Märkte am Morgen: Bitcoin, Amgen, Tesla, Spotify, Shopify, Bayer, Siemens Energy, Allianz, RWE | Der schöne Wochenauftakt für den DAX ist bereits wieder verpufft. Gestern schloss er 2,13 Prozent tiefer bei 19.033 Punkten. Heute scheint erst einmal Richtungssuche angesagt. Im Laufe des Tages stehen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 4,625 | -4,24 % | Inovio Pharmaceuticals Inc. Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) reported Loss for third quarter that decreased from last yearThe company's earnings totaled -$25.17 million, or -$0.89 per share. This... ► Artikel lesen | |
| INFLARX | 1,942 | +0,41 % | InflaRx N.V.: InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update | Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,808 | +1,35 % | Cardiol Therapeutics Inc: Cardiol Therapeutics joins PRISM Emerging Biotech Index | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,750 | -0,76 % | Cathie Wood's ARK sells Unity, buys Pacific Biosciences stock | ||
| REDHILL BIOPHARMA | 7,190 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| CURIS | 3,820 | +0,53 % | Curis Inc Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Curis Inc (CRIS) released Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line totaled -$10.09... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,512 | +3,27 % | BioXcel Therapeutics-Aktie erreicht 52-Wochen-Tief bei 0,50 US-Dollar | ||
| COHERUS | 0,732 | -0,79 % | Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript | ||
| ESPERION | 2,077 | +3,80 % | Esperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,555 | -0,89 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q3 2024 Financial and Business Updates | Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number... ► Artikel lesen | |
| FIBROGEN | 0,320 | -9,07 % | FibroGen, Inc.: FibroGen Reports Third Quarter 2024 Financial Results | Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with... ► Artikel lesen | |
| KARYOPHARM | 0,812 | +1,42 % | Karyopharm Therapeutics Inc. - 8-K, Current Report | ||
| BIOLINERX | 0,408 | -5,99 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates | - Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,724 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.
